Report : South & Central America Enzymatic DNA Synthesis Market Forecast to 2028 – COVID-19 Impact and Regional Analysis – by Product Type (Custom DNA Synthesis and DNA Library Synthesis), Application (Synthetic Biology, Genetic Engineering, Therapeutic Antibodies, Vaccine Design, and Others), Technology (SOLA, CRISPR, PCR, and Others), and End User (Academic & Research Institutes, Biotech & Pharmaceutical Companies, Diagnostic Laboratories, and Others)
At 43.1% CAGR, the South & Central America Enzymatic DNA Synthesis Market is speculated to be worth US$ 112.02 million by 2028, says Business Market Insights
According to Business Market Insights research, the South & Central America enzymatic DNA synthesis market was valued at US$ 13.04 million in 2022 and is expected to reach US$ 112.02 million by 2028, registering a CAGR of 43.1% from 2022 to 2028. Growing demand for enzymatic DNA synthesis procedure and growing demand for personalized medicine and DNA data storage are the critical factors attributed to the South & Central America enzymatic DNA synthesis market expansion.
Enzymatic approaches are the most attractive and are scalable, stereospecific, and environmentally benign. Enzymes can mediate mismatch recognition, enabling selective annealing of complementary strands, reducing the number of steps in each elongation cycle by eliminating the need for coupling reagents, and lowering the dependence on organic solvents. The enzymatic synthesis is inherently simpler than the chemical alternative and has the crucial potential to be much more precise than the chemical approach, introducing fewer errors into the code. This makes it possible to produce much longer sequences without causing cumbersome, inefficient, costly cleanups or workarounds. Several start-up companies and academic institutes are developing novel enzyme-based DNA synthesis technologies, which are believed to be the first breakthrough in DNA synthesis technology in ~40 years. These methods would significantly reduce costs and production time. As several enzyme companies are now active in the enzymatic DNA synthesis space, different business models have emerged with an increasing focus on DNA assembly and benchtop printers, creating opportunities for The South & Central America enzymatic DNA synthesis market. DNA Script offers the Syntax instrument as a benchtop DNA synthesizer in a similar size as a HiSeq sequencer developed by Illumina. This synthesizer can generate 60 bp oligonucleotides in pure form for immediate use within 6 hours. In addition, the next generation of on-demand DNA synthesizers is likely to provide unprecedented accuracy, scalability, and speed, democratizing access to this technology and realizing the full promise of synthetic DNA to accelerate the development of tomorrow's medicine. These projected developments in the DNA synthesis landscape are expected open new opportunities for companies operating in the South & Central America enzymatic DNA synthesis market.
On the contrary, high costs and complex procedures hurdles the growth of South & Central America enzymatic DNA synthesis market.
Based on product type, the South & Central America enzymatic DNA synthesis market is bifurcated into custom DNA synthesis and DNA library synthesis. The DNA library synthesis segment held 65.7% share of South & Central America enzymatic DNA synthesis market in 2022, amassing US$ 8.57 million. It is projected to garner US$ 72.66 million by 2028 to expand at 42.8% CAGR during 2022–2028.
Based on application, the South & Central America enzymatic DNA synthesis market is segmented into synthetic biology, genetic engineering, therapeutic antibodies, vaccine design, and others. The synthetic biology segment held 49.9% share of South & Central America enzymatic DNA synthesis market in 2022, amassing US$ 6.50 million. It is projected to garner US$ 55.07 million by 2028 to expand at 42.8% CAGR during 2022–2028.
Based on end user, the South & Central America enzymatic DNA synthesis market is segmented into academic & research institutes, biotech & pharmaceutical companies, diagnostic laboratories, and others. The biotech & pharmaceutical companies segment held 48.9% share of South & Central America enzymatic DNA synthesis market in 2022, amassing US$ 6.38 million. It is projected to garner US$ 54.11 million by 2028 to expand at 42.8% CAGR during 2022–2028.
Based on country, the South & Central America enzymatic DNA synthesis market has been categorized into Brazil, Argentina, and the Rest of South & Central America. Our regional analysis states that the Rest of South & Central America captured 38.0% share of South & Central America enzymatic DNA synthesis market in 2022. It was assessed at US$ 4.96 million in 2022 and is likely to hit US$ 41.79 million by 2028, exhibiting a CAGR of 42.7% during the forecast period.
Key players profiles in the South & Central America enzymatic DNA synthesis market report DNA Script; GenScript Biotech Corporation; Synbio Technologies; Telesis Bio Inc; and Twist Bioscience, among others.
Contact Us
Contact Person: Sameer Joshi
Phone: +1-646-491-9876
Email Id: sales@businessmarketinsights.com